Molecule inhibits drug-resistant bacteria in mice with pneumonia, UTIs

By The Science Advisory Board staff writers

August 10, 2022 -- A new molecule that inhibits drug-resistant bacteria in laboratory experiments, as well as in mice with pneumonia and urinary tract infections (UTIs), has potential for treating stubborn infections in humans, according to researchers.

In their study, published August 10 in ACS Central Science, the researchers reported that a modified compound, dubbed fabimycin, prevented growth for more than 300 strains of drug-resistant bacterial clinical isolates, including Escherichia coli, while remaining relatively inactive toward certain gram-positive pathogens and some typically harmless bacteria that live in or on the human body.

The new molecule also reduced the amount of drug-resistant bacteria in mice with pneumonia or UTIs to preinfection levels or below, performing as well as or better than existing antibiotics at similar doses.

"Fabimycin demonstrates activity in multiple mouse models of infection caused by gram-negative bacteria, including a challenging urinary tract infection model," according to the study's authors. "Fabimycin has translational promise, and its discovery provides additional evidence that antibiotics can be systematically modified to accumulate in gram-negative bacteria and kill these problematic pathogens."


Copyright © 2022 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.